Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Pre-Mkt 02-27 07:02:49 EST

21.64

+0.22

+1.03%

盘前21.63

-0.01-0.05%

07:01 EST

High22.12	Low20.82	Vol2.22M
Open21.44	D1 Closing21.42	Amplitude6.07%
Mkt Cap2.77B	Tradable Cap1.69B	Total Shares127.83M
T/O48.20M	T/O Rate2.84%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":21.64,"timestamp":1772139600000,"preClose":21.42,"halted":0,"volume":2222082,"hourTrading":{"tag":"盘前","latestPrice":21.63,"preClose":21.64,"latestTime":"07:01 EST","volume":4828,"amount":104098.308844,"timestamp":1772193683134,"change":-0.01,"changeRate":-0.000462,"amplitude":0.022643},"delay":0,"changeRate":0.010270774976657276,"floatShares":78119932,"shares":127829909,"eps":0.172407,"marketStatus":"Pre-Mkt","change":0.22,"latestTime":"02-27 07:02:49 EST","open":21.44,"high":22.12,"low":20.82,"amount":48204529.213374004,"amplitude":0.060691,"askPrice":24.74,"askSize":100,"bidPrice":21.59,"bidSize":1,"shortable":3,"etf":0,"ttmEps":0.172407,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772202600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":21.64,"preHourTrading":{"tag":"盘前","latestPrice":21.63,"preClose":21.64,"latestTime":"07:01 EST","volume":4828,"amount":104098.308844,"timestamp":1772193683134,"change":-0.01,"changeRate":-0.000462,"amplitude":0.022643},"postHourTrading":{"tag":"盘后","latestPrice":21.64,"preClose":21.64,"latestTime":"19:27 EST","volume":14247,"amount":308314.64,"timestamp":1772152037605,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9148363272684473,"impliedVol":0.5194,"impliedVolPercentile":0.268},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"1188667814","title":"Stock Track | Apellis Pharmaceuticals Plummets 5.17% Intraday Following Analyst Price Target Cuts and Neutral Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1188667814","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188667814?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:53","pubTimestamp":1772034817,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet by 5.17% during intraday trading on Wednesday, reflecting negative market sentiment toward the biopharmaceutical company.The sharp...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0},{"id":"2614940080","title":"Apellis price target lowered to $18 from $20 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2614940080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614940080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:36","pubTimestamp":1772026613,"startTime":"0","endTime":"0","summary":"Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Ape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4588","LU1093756325.SGD","BK4505","APLS","BK4585","BK4139"],"gpt_icon":0},{"id":"2614082173","title":"Cantor Fitzgerald Remains a Buy on Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082173?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:56","pubTimestamp":1772024188,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Apellis Pharmaceuticals yesterday and set a price target of $35.00. The compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4585","BK4588","BK4139","LU1093756325.SGD","LU1093756168.USD","APLS"],"gpt_icon":0},{"id":"2614089070","title":"Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089070?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:01","pubTimestamp":1772020860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 07:01 ET (12:01 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS","BK4505","BK4139","BK4588","LU1093756168.USD","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2614088827","title":"Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614088827","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614088827?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:07","pubTimestamp":1772014047,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $24.00. Merle co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS"],"gpt_icon":0},{"id":"2614749967","title":"Wedbush Adjusts Apellis Pharmaceuticals Price Target to $18 From $20, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614749967","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614749967?lang=en_us&edition=fundamental","pubTime":"2026-02-25 01:21","pubTimestamp":1771953683,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of overweight and mean price target of $33.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4585","BK4588","BK4139","APLS","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2614745249","title":"Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614745249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614745249?lang=en_us&edition=fundamental","pubTime":"2026-02-25 00:10","pubTimestamp":1771949426,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palisade Bio (PALI – Research Report) and Apellis Ph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palisade-bio-pali-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palisade-bio-pali-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSX","BLSG","XBI","LU1093756325.SGD","BK4588","LU0128526141.USD","PALI","LU0029874061.USD","LU1093756168.USD","APLS","BK4139","BK4581","BK4137","BK4505","LABU","BK4112","BK4585","BK4007"],"gpt_icon":0},{"id":"1117776674","title":"Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1117776674","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117776674?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:35","pubTimestamp":1771943726,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.The sharp decline followed the release of the company's fourth-quarter 2025...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0},{"id":"2613808716","title":"Apellis Q4 product revenue driven by SYFOVRE sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2613808716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613808716?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:12","pubTimestamp":1771935175,"startTime":"0","endTime":"0","summary":"Apellis Q4 product revenue driven by SYFOVRE salesOverviewBiopharmaceutical company reported Q4 product revenue of $190 mln, driven by SYFOVRE salesNet income for 2025 was $22 mln, compared to a net l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK0HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4585","BK4505","LU1093756325.SGD","BK4139","BK4588","APLS"],"gpt_icon":0},{"id":"2613891716","title":"Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2613891716","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613891716?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:09","pubTimestamp":1771934993,"startTime":"0","endTime":"0","summary":"Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS"],"gpt_icon":0},{"id":"2613715055","title":"Apellis Pharmaceuticals Q4 EPS $(0.47) Misses $(0.38) Estimate, Sales $199.913M Beat $199.222M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715055","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715055?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:07","pubTimestamp":1771934821,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.38) by 23.36 percent. This is a 62.07 percent decrease over losses of $(0.29) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50809199/apellis-pharmaceuticals-q4-eps-0-47-misses-0-38-estimate-sales-199-913m-beat-199-222m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","APLS","BK4588","BK4505","BK4139","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2613152717","title":"BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD 0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2613152717","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613152717?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934745,"startTime":"0","endTime":"0","summary":"BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD 0.47\n\n\nFeb 24 (Reuters) - Apellis Pharmaceuticals Q4 operating expenses USD 251.055 million.\n\nQ4 product revenue USD 190.341 million\nQ4 net income USD -58.951 million\nQ4 operating income USD -51.142 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLXA9184B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU1093756325.SGD","LU1093756168.USD","BK4505","BK4139","APLS"],"gpt_icon":0},{"id":"2613715497","title":"Apellis Pharmaceuticals Q4 Operating Income USD -51.142 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715497?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLXA9184B:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","APLS","BK4505","LU1093756168.USD","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"2613671308","title":"Apellis posts FY 2025 licensing and other revenue of USD 314.4 million, up 340%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613671308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613671308?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:57","pubTimestamp":1771934265,"startTime":"0","endTime":"0","summary":"Apellis reported FY 2025 total revenue of USD 1.0 billion, including net product revenue of USD 689.4 million  and licensing and other revenue of USD 314.4 million , driven primarily by a USD 275.0 million upfront payment under a royalty buy-down agreement with Swedish Orphan Biovitrum . Net income for FY 2025 was USD 22.4 million, with net operating income of USD 55.4 million. Operating expenses in FY 2025 totaled USD 948.4 million, including cost of sales of USD 102.2 million , R&D of USD 295.9 million , and SG&A of USD 550.3 million ; interest expense was USD 44.3 million  and interest income was USD 13.1 million . By product, FY 2025 U.S. net product revenue was USD 586.9 million for Syfovre and USD 102.4 million for Empaveli. Key updates included initiation of a Phase 2 multi-dose trial in June 2025 combining Syfovre with APL-3007  in geographic atrophy, and the start of two pivotal Empaveli trials in Q4 2025 for primary focal segmental glomerulosclerosis and delayed graft functio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL97PfLw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","LU1093756325.SGD","BK4505","LU1093756168.USD","APLS"],"gpt_icon":0},{"id":"2613790840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613790840?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:00","pubTimestamp":1771930800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Albany Intl Corp. Class A                        4Q       .61        BMO. Bank of Nova Scotia                              1Q      1.43    6:15 AM. Bowhead Specialty Hldgs Inc.                     4Q       .44    7:00 AM. Clean Energy Fuels Corp.                        4Q      (.05)   4:05 PM. Controladora Vuela Comp de Aviacion             4Q       .20        AMC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AHCO","AII","AMT","EXPD","CGBD","AXGN","FERG","ATEC","ELAN","EXLS","CORT","CYTK","ARVN","AS","CAVA","DDS","ADTN","ASR","DRS","ACHC","CECO","CLVT","CDNA","ESTA","ATRO","DOCN","ECG","ESPR","ABCL","BRSL","BOW","BNS","CIFR","CCC","EOG","AIN","AWI","BXC","APLS","CWH","DAWN","CLNE","EVH","CSGP","HSBC","AXON","ACAD","CBLL","BBIO"],"gpt_icon":1},{"id":"2612240710","title":"BRIEF-Apellis Announces Eight Oral Presentations At The 49Th Macula Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612240710","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612240710?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:55","pubTimestamp":1771505717,"startTime":"0","endTime":"0","summary":"BRIEF-Apellis Announces Eight Oral Presentations At The 49Th Macula Society Annual MeetingFeb 19 (Reuters) - Apellis Pharmaceuticals Inc APLS.O:APELLIS ANNOUNCES EIGHT ORAL PRESENTATIONS AT THE 49TH M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABL73VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","APLS","BK4505","LU1093756325.SGD","BK4139","LU1093756168.USD","BK4585"],"gpt_icon":0},{"id":"2612208404","title":"Apellis to Present Eight Oral Talks at Macula Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612208404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612208404?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:01","pubTimestamp":1771502484,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals said it will present eight oral abstracts at the 49th Macula Society Annual Meeting, taking place Feb. 25–28, 2026, in San Diego, including five-year GALE extension results on SYFOVRE  in a Feb. 27 presentation titled “Earlier Treatment Yields Better Outcomes: 5-Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD.”Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL7nmpGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU1093756168.USD","NDAQ","BK4139","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","BK4505","LU1093756325.SGD","APLS","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"1131596076","title":"Earning Preview: Apellis Pharmaceuticals Inc. revenue is expected to increase by 0.44%, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1131596076","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131596076?lang=en_us&edition=fundamental","pubTime":"2026-02-17 15:09","pubTimestamp":1771312165,"startTime":"0","endTime":"0","summary":"AbstractApellis Pharmaceuticals Inc. will report its quarterly results on February 24, 2026 Pre-Market; this preview consolidates company guidance, recent operating updates, and analyst commentary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Apellis Pharmaceuticals Inc. revenue is expected to increase by 0.44%, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS"],"gpt_icon":0},{"id":"2610064282","title":"Apellis Pharmaceuticals Inc. to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2610064282","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610064282?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:00","pubTimestamp":1770724812,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results. The live audio webcast and accompanying slides will be accessible through the \"Events and Presentations\" page of the \"Investors and Media\" section of the company's website. A replay will be available for 30 days following the event. To access the live call by phone, please pre-register for the call here.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLb17JKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","APLS","BK4505","LU0314104364.USD","LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD","SG9999014021.USD","NDAQ","BK4588","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","LU1093756325.SGD","LU1093756168.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2607071746","title":"How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607071746","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607071746?lang=en_us&edition=fundamental","pubTime":"2026-01-31 16:33","pubTimestamp":1769848420,"startTime":"0","endTime":"0","summary":"In recent days, Apellis Pharmaceuticals reported strong momentum for its complement inhibitor Empaveli, including preliminary Q4 2025 U.S. net product revenue of about US$35.00 million, reflecting year-over-year growth and rapid uptake in treating paroxysmal nocturnal hemoglobinuria and other rare conditions with high unmet medical needs.\nInvestor attention has also been drawn to analyst commentary highlighting Empaveli’s early market penetration and underappreciated commercial potential...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-empavelis-rapid-uptake-and-q4-2025-revenue-momentum-will","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-empavelis-rapid-uptake-and-q4-2025-revenue-momentum-will","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["APLS","ISBC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0509},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.2151},{"period":"1year","weight":-0.1781},{"period":"ytd","weight":-0.1385}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.555556,"avgChangeRate":0.024329},{"month":3,"riseRate":0.5,"avgChangeRate":0.022263},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}